For US health-care professionals only. Prescribing Information

Single IV or oral dose prior to chemotherapy as part of an antiemetic regimen1

VARUBI IV is the first NK-1 RA in a ready-to-use vial1-3

Other Drug Interactions

  • Strong CYP3A4 inducers: Avoid use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers (eg, rifampin) as significantly reduced plasma concentrations of VARUBI can decrease the efficacy of VARUBI.
  • BCRP and P‐gp substrates with a narrow therapeutic index: Oral VARUBI is an inhibitor of breast cancer resistance protein (BCRP) and P‐glycoprotein (P-gp). Increased plasma concentrations of BCRP substrates (eg, methotrexate, topotecan, or irinotecan) and P-gp substrates (eg digoxin) with a narrow therapeutic index may result in potential adverse reactions. Monitor for adverse reactions related to the concomitant drug if use with VARUBI cannot be avoided. Monitor digoxin concentrations with concomitant use of VARUBI, and adjust the dosage as needed to maintain therapeutic concentrations.
  • Warfarin: Monitor INR and prothrombin time and adjust the dosage of warfarin, as needed, to maintain target INR.

 

IV: Ready-to-use, single-dose vial of injectable emulsion (166.6 mg infused over 30 min) requires no reconstitution or refrigeration1

  • Store at 20°C to 25°C (68°F to 77°F)

IV, intravenous; NK-1, neurokinin 1; RA, receptor antagonist.

 

 

See detailed preparation instructions

VARUBI® (rolapitant) ready-to-use vial
VARUBI® (rolapitant) tablets

Oral: Single-dose wallet card contains two 90-mg tablets1

  • Tablets can be taken with or without food

 

 

 

 

VARUBI® (rolapitant) ready-to-use vial

IV: Ready-to-use, single-dose vial of injectable emulsion (166.6 mg infused over 30 min) requires no reconstitution or refrigeration1

  • Store at 20°C to 25°C (68°F to 77°F)

IV, intravenous; NK-1, neurokinin 1; RA, receptor antagonist.

VARUBI® (rolapitant) tablets

Oral: Single-dose wallet card contains two 90-mg tablets1

  • Tablets can be taken with or without food

VARUBI dosing regimen1

Combined antiemetic regimen dosing with VARUBI, a 5-HT3 RA, and dexamethasone for the prevention of nausea and vomiting in the delayed phase associated with HEC and MEC1

VARUBI® (rolapitant) dosing regimen

5-HT3, 5-hydroxytryptamine-3 (serotonin); HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; RA, receptor antagonist.

IV preparation instructions step 1

Use aseptic technique to prepare the vial and IV line

IV preparation instructions step 2

Insert a vented IV set through vial septum, open vent

IV preparation instructions step 3

Hang vial,
infuse 92.5 mL over 30 minutes

  • Do not use if particulate matter or discoloration is present or if contamination is suspected
  • Once the stopper is punctured, use immediately
  • Do not dilute VARUBI injectable emulsion

adobe_button.pngDownload a Dosing and Administration Guide for VARUBI